Electra Therapeutics’ upsized IPO raised $350 million to fund a potential first-in-class precision immunology drug aimed at a rare hyperinflammatory disorder without FDA-approved treatments. The debut also detailed plans for clinical development as the company works to convert early science into registrational evidence. At the same time, clinical-stage biotechs Marea Therapeutics and Sensorion signaled their intent to enter U.S. public markets, according to the report. That combination of capital raises and planned listings highlights investor appetite for differentiated early-stage immunology approaches. In sector terms, the story is about pipeline financing for immunomodulators—areas where trial execution bandwidth and biomarker strategy often determine speed to proof.